 |
160 Products |  |
813 Diseases | | 160 Products |
|
1552 Trials |  |
75151 News |  |
| «12345678910111213...858859» |
- || efruxifermin (AKR-001) / Akero Therap
P2 data, Journal, Combination therapy: Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study. (Pubmed Central) - Dec 22, 2024
P2b
The tolerability profile of efruxifermin added to GLP-1RA appeared comparable to that of either drug alone, while also significantly reducing HFF and noninvasive markers of fibrosis in patients with MASH and T2D. Liver health in patients already on a GLP-1RA may be further improved by addition of efruxifermin.
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Journal, Real-world evidence, Head-to-Head, Real-world, Metastases: Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry. (Pubmed Central) - Dec 21, 2024
P
This head-to-head comparison revealed no difference in PFS and OS between PALBO and RIBO, however, a trend to longer PFS and OS with RIBO was observed in the subgroup of patients with TFI <12?months. Side effects experienced with PALBO and RIBO highlight the important toxicities to be addressed during treatment decision.
- | Stivarga (regorafenib) / Bayer
Journal, BRCA Biomarker, PARP Biomarker: Regorafenib induces DNA damage and enhances PARP inhibitor efficacy in pancreatic ductal carcinoma. (Pubmed Central) - Dec 21, 2024
Side effects experienced with PALBO and RIBO highlight the important toxicities to be addressed during treatment decision. Together, these findings demonstrate that regorafenib can attenuate DNA damage response and potentiate the efficacy of PARP inhibitors in PDAC tumors.
- | Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Journal, Surgery: Effect of romosozumab administration on proximal junctional kyphosis in corrective spinal fusion surgery. (Pubmed Central) - Dec 21, 2024
Administration of romosozumab 2 months before surgery enhanced bone mineral density and strength, leading to better surgical outcomes and fewer complications. Further long-term studies are needed to confirm these findings and optimize treatment protocols.
- | Imlygic (talimogene laherparepvec) / Amgen
Retrospective data, Journal, IO biomarker: Genetic Factors Associated with Clinical Response in Melanoma Patients Treated with Talimogene Laherparapvec: A Single-Institution Retrospective Analysis. (Pubmed Central) - Dec 21, 2024
Further long-term studies are needed to confirm these findings and optimize treatment protocols. This work describes the experience using T-VEC in melanoma at a single institution and highlights the presence of TERT promotor mutations as a possible driver of clinical response.
- || Tepezza (teprotumumab-trbw) / Roche, Amgen
Clinical, Journal: The Rate of Retreatment in Patients treated with teprotumumab: A Multicenter Study of 119 Patients with 1 year Follow Up. (Pubmed Central) - Dec 21, 2024
In patients receiving a full course of teprotumumab therapy, the rate of re-treatment was 24%. Age was the only driver of re-treatment.
- | Prolia (denosumab) / Amgen
Journal: Denosumab in osteoporosis management for diabetes patients: insights from clinical trials and explorations for dual benefit. (Pubmed Central) - Dec 21, 2024
Age was the only driver of re-treatment. No abstract available
- | Tepezza (teprotumumab-trbw) / Roche, Amgen
Journal: Efficacy, Safety, and Recurrence in Older Thyroid Eye Disease Patients Undergoing Teprotumumab Treatment. (Pubmed Central) - Dec 20, 2024
One patient with diabetes experienced an A1C rise requiring insulin. One patient had recurrence with increasing proptosis and recurrence of diplopia.
- | Iclusig (ponatinib) / Takeda, Otsuka, Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Biomarker, Journal: Philadelphia Chromosome as a Clinically Favorable Prognostic Factor of B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Transplant-Ineligible Elderly Patients in the Era of Molecular-Targeted Therapy. (Pubmed Central) - Dec 20, 2024
Background and objective There is scarce data on the treatment outcomes of B-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (B-ALL/LBL) in elderly patients in the era of tyrosine kinase inhibitors (TKIs), blinatumomab, and inotuzumab ozogamicin...Dasatinib combined with prednisolone was the most common induction therapy for Ph-positive ALL (88.2%)...There was no difference in relapse-free survival (RFS); 13 patients (76.5%) with Ph-positive ALL were treated with ponatinib (salvage therapy, n=7; consolidation or maintenance therapy in CR, n=6)...The other patient with Ph-negative ALL for primary refractory achieved CR but relapsed after the fourth course of inotuzumab ozogamicin. Conclusions Elderly patients with Ph-positive ALL showed significantly longer OS and EFS than those with Ph-negative ALL in the era of molecular-targeted therapy.
- | Ibrance (palbociclib) / Pfizer
Journal, Metastases: Incidence of patient-reported fatigue developing on palbociclib and endocrine therapy for advanced HR+ HER2- breast cancer. (Pubmed Central) - Dec 20, 2024
One-quarter of patients with HR+?HER2- MBC initiating palbociclib report rapidly emergent clinically meaningful fatigue, often with severe symptoms and functional interference. Treatment-emergent fatigue is associated with both pretreatment (lower ANC levels, longer sleep duration) and on-treatment (long sleep duration) hematologic and nonhematologic profiles.
- | GP40141 (romiplostim biosimilar) / Geropharm, Nplate (romiplostim) / Amgen
Journal: Optimization of Romiplostim Biosimilar Efficacy Trial Using In Silico Clinical Trial Approach for Patients With Immune Thrombocytopenia. (Pubmed Central) - Dec 20, 2024
Treatment-emergent fatigue is associated with both pretreatment (lower ANC levels, longer sleep duration) and on-treatment (long sleep duration) hematologic and nonhematologic profiles. Since the planned trial includes both patients na
- || Review, Journal: Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways. (Pubmed Central) - Dec 20, 2024
While multiple therapeutic antibodies have been approved for clinical use, scientists are still working on ways to improve on current treatment approaches. Here, we provide context to understand therapeutic targeting strategies and their limitations, discussing both knowledge gaps and promising future directions to enhancing clinical efficacy in allergic disease management.
- || volagidemab (REMD-477) / Amgen, REMD Bio, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Clinical, Journal: Combination SGLT2 Inhibitor and Glucagon Receptor Antagonist Therapy in Type 1 Diabetes: A Randomized Clinical Trial. (Pubmed Central) - Dec 20, 2024
Glucagon antagonism enhances the therapeutic effects of SGLT2 inhibition in type 1 diabetes. Combination therapy improves glycemic control, reduces insulin dosing, and suggests a strategy to unlock the benefits of SGLT2 inhibitors while mitigating the risk of diabetic ketoacidosis.
- | Ibrance (palbociclib) / Pfizer
Preclinical, Journal: Discovery of Palbociclib as a potent c-Myc G4 stabilizer for lung cancer treatment using molecular docking, molecular dynamics simulation, and in vitro activity evaluation. (Pubmed Central) - Dec 20, 2024
Through circular dichroism (CD), molecular docking, and molecular dynamics (MD) simulation, we have provided evidence that Palbociclib enhances the structural stability of c-Myc G4 while exhibiting a high binding affinity to its ligand's binding site on c-Myc G4. These results suggest that Palbociclib holds promise as a novel c-Myc G4 stabilizer for treating cancers associated with abnormal c-Myc activity; further optimization and development are warranted.
- ||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Trial completion: WAYPOINT: Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis (clinicaltrials.gov) - Dec 20, 2024
P3, N=416, Completed, Sponsor: AstraZeneca
These results suggest that Palbociclib holds promise as a novel c-Myc G4 stabilizer for treating cancers associated with abnormal c-Myc activity; further optimization and development are warranted. Active, not recruiting --> Completed
- |||||| xaluritamig (AMG 509) / Amgen
Enrollment open, Trial completion date, Trial primary completion date: Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Dec 20, 2024
P3, N=675, Recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial completion date: Nov 2029 --> May 2030 | Trial primary completion date: Aug 2028 --> Dec 2028
- |||| Opdualag (nivolumab/relatlimab-rmbw) / BMS, Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date: RELATIVITY-123: A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 20, 2024
P3, N=700, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting | Trial completion date: Nov 2029 --> May 2030 | Trial primary completion date: Aug 2028 --> Dec 2028 Trial completion date: May 2028 --> Jul 2025 | Trial primary completion date: Jan 2025 --> Jul 2025
- ||||| Imdelltra (tarlatamab-dlle) / Amgen
New P2 trial: DeLLphi-309: A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC (clinicaltrials.gov) - Dec 20, 2024
P2, N=240, Not yet recruiting, Sponsor: Amgen
- || Itovebi (inavolisib) / Roche
Trial completion date, Trial primary completion date: INAVO120: To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer (clinicaltrials.gov) - Dec 20, 2024
P1, N=200, Active, not recruiting, Sponsor: Genentech, Inc.
Trial completion date: May 2028 --> Jul 2025 | Trial primary completion date: Jan 2025 --> Jul 2025 Trial completion date: Nov 2024 --> Dec 2026 | Trial primary completion date: Nov 2024 --> Dec 2026
- | Opdivo (nivolumab) / BMS, Stivarga (regorafenib) / Bayer
Trial completion date, Trial primary completion date: REGINA: Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer (clinicaltrials.gov) - Dec 20, 2024
P2, N=72, Recruiting, Sponsor: Jules Bordet Institute
Trial completion date: Nov 2024 --> Dec 2026 | Trial primary completion date: Nov 2024 --> Dec 2026 Trial completion date: Jan 2030 --> Dec 2030 | Trial primary completion date: Jan 2025 --> Jan 2026
- | Repatha (evolocumab) / Amgen, Astellas
Journal: PCSK9 promotes vascular neointimal hyperplasia through non-lipid regulation of vascular smooth muscle cell proliferation, migration, and autophagy. (Pubmed Central) - Dec 19, 2024
We aim to explore the impact of Proprotein convertase subtilisin-kexin type 9 (PCSK9) and its inhibitor evolocumab on neointimal hyperplasia...The proliferative effects of PCSK9 may be mediated by the PI3K/AKT/mTOR signaling pathway. These data provide additional evidence for PCSK9i in cardiovascular disease beyond the low-density lipoprotein (LDL)-lowering benefit.
- | efruxifermin (AKR-001) / Akero Therap
Preclinical, Journal: Construction and Expression of Fc-FGF21 by Different Expression Systems and Comparison of Their Similarity and Difference with Efruxifermin by In Vitro and In Vivo Studies. (Pubmed Central) - Dec 19, 2024
Taken together, this study demonstrates a good example of how to develop and validate a biosimilar for therapeutic purposes. In future, more efforts, such as mutation to FGF21 or linking FGF21 with effective antibody to form dual targets, could be done to obtain more effective FGF21 analogs.
- || Review, Journal: Infections in Sj (Pubmed Central) - Dec 19, 2024
Emerging therapies, such as ianalumab, iscalimab, dazodalibep, and remibrutinib, show efficacy in reducing disease activity but also present infection risks, with reports of upper respiratory infections and serious cases, including pneumonia and COVID-19. By exploring these infection-related challenges, this review underscores the importance of understanding the infection-autoimmunity relationship to improve outcomes for patients with SjD and similar autoimmune conditions.
- | Lumakras (sotorasib) / Amgen
Preclinical, Journal: Preclinical Evaluation of [124I]-Sotorasib for the Imaging of Kirsten Rat Sarcoma G12C Mutant Tumors. (Pubmed Central) - Dec 19, 2024
Toward this goal, we have developed a sotorasib-based molecular agent for PET imaging and tested its efficacy in targeting tumor lesions with KRAS G12C mutations. Here, we describe the synthesis, in vitro and in vivo evaluation of an [124I]I-Sotorasib analog in targeting G12C mutant tumor lesions using PET imaging.
- || Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB, odanacatib (MK-0822) / Merck (MSD)
Review, Journal: The Management of Osteoporosis in Chronic Kidney Disease: A Review of Diagnostic and Therapeutic Approaches. (Pubmed Central) - Dec 19, 2024
While traditional osteoporosis treatments such as bisphosphonates, denosumab, and teriparatide have been adapted for CKD patients, recent innovations have introduced agents aimed at enhancing bone mass and reducing fracture incidence...Osteoporosis management in CKD patients necessitates a personalized approach guided by the disease's stage and individual profile. This review underscores the potential of emerging therapies and emphasizes the need for further research to refine treatment protocols, aiming to enhance patient outcomes in this complex population.
- || Ibrance (palbociclib) / Pfizer
Clinical, Journal: Oral self-management of palbociclib using mobile technology: Findings from a nurse-led randomized controlled trial. (Pubmed Central) - Dec 19, 2024
P=N/A
Given the importance of cancer treatments and the difficulties patients experience during these treatments, text messages using smartphones can actively improve patients' engagement and their ability to manage their treatment regimens. ClinicalTrials.gov; ID: NCT04216576.
- | Prolia (denosumab) / Amgen
Journal: Case Report: single low-dose of denosumab as a trigger of MRONJ development in a patient with osteoporosis after bisphosphonate therapy. (Pubmed Central) - Dec 19, 2024
Besides these, literature reports one patient who developed MRONJ after a single dose of DMB following romosozumab treatment and five cases developing MRONJ after a single dose of DMB even without any previous ARD treatment. We suggest that before DMB therapy is initiated, all factors predisposing to MRONJ development should be considered.
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Ibrance (palbociclib) / Pfizer, Verzenio (abemaciclib) / Eli Lilly
Clinical, Journal, Real-world evidence, Real-world, Metastases: Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2-metastatic breast cancer patients: a multicenter study (YOUNGBC-28). (Pubmed Central) - Dec 19, 2024
P
Palbociclib, abemaciclib, and dalpiciclib demonstrated comparable efficacy in Chinese patients with advanced HR+/HER2- MBC. ClinicalTrials.gov identifier: NCT06344780.
- | Prolia (denosumab) / Amgen
Journal: Course and treatment of severe osteoporosis complicated by calciphylaxis: a case report. (Pubmed Central) - Dec 19, 2024
This approach rapidly decreased TRACP-5b levels and arrested the chain of vertebral fractures. We concluded that to maintain the quality of life of patients with CUA, early treatment of primary skin lesions as well as comorbid conditions is essential.
- | Repatha (evolocumab) / Amgen, Astellas
Journal, Real-world evidence, Real-world: Real-World safety and effectiveness of evolocumab in primary hypercholesterolemia and mixed dyslipidemia in Saudi Arabia. (Pubmed Central) - Dec 19, 2024
We concluded that to maintain the quality of life of patients with CUA, early treatment of primary skin lesions as well as comorbid conditions is essential. Evolocumab use significantly reduced LDL and total cholesterol levels at 6, 12, 18, and 24
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Journal, FDG PET, Metastases: The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting. (Pubmed Central) - Dec 19, 2024
Most patients received fulvestrant (31 patients, 79%), whereas eight patients (21%) were treated with letrozole...FDG-PET-CT performed before cyclin-dependent kinase 4/6 inhibitor commencement is a valuable prognostic tool in hormone receptor-positive human epidermal growth factor receptor 2-negative advanced breast cancer. Patients with SUVmax less than 8.4 experienced extended progression-free survival compared to those with higher SUVmax.
- | Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Journal: N-terminal pro-brain natriuretic peptide and cardiorenal outcome in patients with anaemia in chronic kidney disease. (Pubmed Central) - Dec 19, 2024
Patients with SUVmax less than 8.4 experienced extended progression-free survival compared to those with higher SUVmax. NT-proBNP provides prognostic insights into cardiovascular and renal outcomes among patients with advanced chronic kidney disease experiencing anaemia.
- | Repatha (evolocumab) / Amgen, Astellas
Journal: Type 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers. (Pubmed Central) - Dec 19, 2024
NT-proBNP provides prognostic insights into cardiovascular and renal outcomes among patients with advanced chronic kidney disease experiencing anaemia. The T2D polygenic score serves as an independent predictor of incident diabetes, particularly among individuals with lower distribution of traditional risk factors.
- ||| Imlygic (talimogene laherparepvec) / Amgen
Retrospective data, Journal, Adverse events, Real-world evidence, Real-world: Safety of talimogene laherparepvec: a real-world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS). (Pubmed Central) - Dec 19, 2024
But safety signals were also be detected in 4 unexpected AEs (sepsis, encephalitis, syncope, and lymphadenopathy). Further clinical trials need to be undertaken to facilitate a more comprehensive comprehension of the safety profile of T-VEC.
- Blincyto (blinatumomab) / Astellas, Amgen
Memory T-Cell Add Back and Prophylactic blinatumomab Post Tcr?? Depleted Haploidentical Transplantation Results in Promising Outcomes in Pediatric Patients with High-Risk Acute Leukemia (HCC Ballroom A; In-Person) - Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_1393;
P2
In conclusion, our strategy led to overall promising outcomes. Addback of up to 1x10 7 memory T cells/kg led to robust IR with low rates of severe GVHD and use of prophylactic blina was associated with comparable rates of relapse to TBI-containing regimens.
- Venclexta (venetoclax) / Roche, AbbVie, Blincyto (blinatumomab) / Astellas, Amgen, Darzalex (daratumumab) / J&J
Treatment Trends and Outcomes of Allogeneic Haematopoeitic Cell Transplantation (HCT) in Acute Lymphoblastic Leukaemia (ALL) in Resource Restricted Settings; A Pakistan Blood and Marrow Transplant Group (PBMT) Study (HCC Exhibit Hall 3; In-Person) - Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_1142;
The 5 year overall survival of the entire cohort was 40%. Lack of availability of novel agents make HSCT an effective therapy for ALL in LMICs.
- renizgamglogene autogedtemcel (EDIT-301) / Editas Medicine
Reni-Cel, an Investigational AsCas12a Gene-Edited Cell Medicine, Led to Successful Engraftment, Increased Hemoglobin, and Reduced Transfusion Dependence in Patients with Transfusion-Dependent Beta-Thalassemia Treated in the Edithal Trial (HCC Exhibit Hall 3; In-Person) - Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_1070;
P1/2
Moreover, pts have been transfusion independent for up to 14.5 mos. These findings build on clinical evidence supporting continued investigation of reni-cel in the EdiThal trial.
- Zynteglo (betibeglogene autotemcel) / bluebird bio
Post-Approval, Real-World Experience with Betibeglogene Autotemcel for Transfusion-Dependent Beta Thalassemia (HCC Exhibit Hall 3; In-Person) - Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_1069;
Patients experienced prolonged platelet engraftment time and high platelet transfusion requirements, which were associated with severe bleeding in patients with VOD or HLA Class I alloimmunization. Further studies will seek to mitigate bleeding complications by reducing VOD rates and to explore the impact of HLA Class I alloimmunization in patients receiving beti-cel for TDT.
- Kymriah (tisagenlecleucel-T) / Novartis
Kymriah Real-World Effectiveness and Functional Persistence in Acute Lymphoblastic Leukemia (ALL) (KareALL): A Retrospective Analysis of the Effect of Current Tisagenlecleucel (tisa-cel) Manufacturing in Pediatric and Young Adult Patients (pts) with ALL (HCC Exhibit Hall 3; In-Person) - Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_1033;
In the US, commercial tisa-cel continues to demonstrate compelling clinical benefits. Despite tisa-cel
- CD123-CAR T cell therapy / St. Jude Children's Research Hospital
High Grade CRS and/or IEC-HS in Pediatric Patients with Recurrent/Refractory Leukemia Receiving CD123-CAR T Cells Manufactured in the Presence of Dasatinib (HCC Exhibit Hall 3; In-Person) - Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_1027;
One patient also received ruxolitinib, anakinra and etanercept without benefit, and died of cardiorespiratory failure...Our findings are in contrast with CAR.dasa T-cell products targeting other antigens. Thus, reprogramming CAR T cells with dasatinib cannot be considered a universal approach to improve their antitumor activity.
- melphalan / Generic mfg., fludarabine IV / Generic mfg., thiotepa / Generic mfg.
Fludarabine-Melphalan with Total Body Irradiation or Thiotepa Conditioning Regimens for Adult Patients with Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation (HCC Exhibit Hall 3; In-Person) - Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_957;
Patients with CNS disease who achieved disease control prior to AHSCT have excellent outcomes. Maintenance therapy for high-risk B-cell ALL patients with blinatumomab +/- ponatinib may contribute to the very low relapse rate seen in our study and warrant further investigation.
- briquilimab (JSP191) / Jasper Therap
Targeted Hematopoietic Stem Cell Conditioning through SCF-Blockade (HCC Exhibit Hall 3; In-Person) - Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_951;
Further, only treatment with ACK2 led to robust HSC depletion and enhanced engraftment post HSCT in immunodeficient mice (Fig 1C, D). Similar in vitro and in vivo results were obtained with all ACK2 antibody fragment derivatives which maintained the properties of the full ACK2 mAb (Figs 2A-D).
- briquilimab (JSP191) / Jasper Therap
Allogeneic Hematopoietic Cell Transplantation with Briquilimab (JSP191) Anti-CD117 Antibody-Based Nonmyeloablative Conditioning for GATA2 Deficiency (HCC Exhibit Hall 3; In-Person) - Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_939;
P2
Graft-versus-host disease (GVHD) prophylaxis consisted of cyclophosphamide, tacrolimus, and mycophenolate mofetil... HCT with briquilimab-based nonmyeloablative conditioning results in sustained donor engraftment with full donor myeloid chimerism and minimal toxicity in patients with GATA2 deficiency and may provide benefit for similar syndromes.
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Early Morbimortality in Autologous Stem Cell Transplants Conducted on an Outpatient Basis in Persons with Autoimmune Disease: Experience in 1674 Patients (HCC Exhibit Hall 3; In-Person) - Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_871;
P=N/A
HCT with briquilimab-based nonmyeloablative conditioning results in sustained donor engraftment with full donor myeloid chimerism and minimal toxicity in patients with GATA2 deficiency and may provide benefit for similar syndromes. The transplant began on an outpatient basis in all cases, following the
- Nplate (romiplostim) / Amgen
Single Center Evaluation of Romiplostim in Prolonged Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation (HCC Exhibit Hall 3; In-Person) - Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_823;
However, larger studies are needed to elucidate the role of TPO-RAs after alloHCT. Future analyses include evaluation of treatment response per etiology and optimization of the starting dose.
- Blincyto (blinatumomab) / Astellas, Amgen
Clinical Impact of Pretransplant Blinatumomab in Predominantly Hispanic Adults with B-Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HCC Exhibit Hall 3; In-Person) - Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_816;
This study demonstrates that pretransplant blinatumomab in adult B-ALL patients undergoing allogeneic HSCT is associated with improved DFS and reduced CIR. These findings suggest incorporating blinatumomab into pretransplant treatment strategies may enhance outcomes for adult B-ALL patients undergoing allogeneic HSCT.
- Aucatzyl (obecabtagene autoleucel) / Autolus
Comparison of Obecabtagene Autoleucel (obe-cel) Versus an External Control Arm (ECA) in Adult Patients (pts) with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) (HCC Exhibit Hall 3; In-Person) - Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_812;
P1/2
Obe-cel demonstrated higher ORR and longer OS and EFS vs SOC in matched ECAs. Safety was comparable between treatment groups, demonstrating a positive benefit-risk profile of obe-cel for treatment of adult R/R B-ALL.
- Tecartus (brexucabtagene autoleucel) / Gilead
Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel (Brexu-cel) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) (HCC Exhibit Hall 3; In-Person) - Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_810;
This study represents the largest report to date demonstrating feasibility and outcomes of consolidative alloHCT following commercial brexu-cel in adult B-ALL. Generally low rates of GVHD and NRM were noted in HCT-na
- busulfan / Generic mfg.
Hematopoietic Recovery in Fanconi Anemia Patients Utilizing a Novel Anti-CD117 Antibody-Containing, Irradiation/Busulfan-Free Haploidentical Hematopoietic Stem Cell Transplant Regimen (HCC Ballroom A; In-Person) - Dec 19, 2024 - Abstract #TCTASTCTCIBMTR2025TCT_ASTCT_CIBMTR_767;
M inimal toxicities were observed, with no clinically significant acute GvHD, thereby meeting the primary outcome and safety/tolerability goals of the study . Detailed assessments of recovering hematopoiesis revealed no difference in colony-forming capacity of BM hematopoietic stem and progenitor cells (HSPCs) by 24 weeks post HSCT compared to age-matched controls (n=6; P=0.71) with development of resistance to mitomycin C (MMC) DNA-damage (Fig 2).
- MODULE 5: Biomarker-Based Decision-Making for Patients with mCRC and KRAS G12C Mutations (San Francisco Marriott Marquis, Golden Gate Ballroom ) - Dec 19, 2024 - Abstract #ASCOGI2025ASCO_GI_1001;
This event is organized and accredited by Research To Practice and supported through educational grants provided by GSK, Natera Inc and Pfizer Inc. Rationale for the historical perception of KRAS as an "undruggable" target in advanced cancer Available data with sotorasib and adagrasib monotherapy for mCRC Mechanistic justification for combining KRAS G12C inhibitors with EGFR antibodies for mCRC Published findings with sotorasib/panitumumab and adagrasib/cetuximab for previously treated KRAS G12C-mutated mCRC Recent FDA approval and current clinical role of adagrasib/cetuximab for KRAS G12C-mutated mCRC